A clinical study published in 𝘊𝘭𝘪𝘮𝘢𝘤𝘵𝘦𝘳𝘪𝘤 – 𝘛𝘩𝘦 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘰𝘧 𝘈𝘥𝘶𝘭𝘵 𝘞𝘰𝘮𝘦𝘯’𝘴 𝘏𝘦𝘢𝘭𝘵𝘩 𝘢𝘯𝘥 𝘔𝘦𝘥𝘪𝘤𝘪𝘯𝘦 investigated the impact of myo-inositol supplementation in postmenopausal women diagnosed with metabolic syndrome.

Why it matters:
Menopause is associated with increased insulin resistance, abdominal fat, and cardiometabolic risk. Myo-inositol, a naturally occurring compound involved in insulin signaling and glucose metabolism, offers a non-pharmacological solution with growing scientific backing.

𝗧𝗵𝗲 𝗿𝗲𝘀𝘂𝗹𝘁𝘀?
The study showed significant improvements vs placebo in:
✔ Blood glucose and insulin sensitivity (HOMA index)
✔ Lipid profile (↑ HDL, ↓ LDL & triglycerides)
✔ Blood pressure
…all contributing to a reduced cardiometabolic risk profile.

These findings highlight myo-inositol as a safe, well-tolerated and clinically validated option to support metabolic health during the postmenopausal years—when many women seek alternatives to traditional pharmacological treatments.

Source: Climacteric – International Menopause Society